SEC
ITCI

Seven Eight Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Seven Eight Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,742
Closed -$786K – 680
2024
Q3 		$786K Sell
10,742
-11,168
-51% -$839K 0.07% 465
2024
Q2 		$1.5M Buy
+21,910
New +$1.52M 0.16% 219
2023
Q3 		– Sell
-6,625
Closed -$419K – 782
2023
Q2 		$419K Sell
6,625
-7,030
-51% -$438K 0.07% 345
2023
Q1 		$739K Buy
+13,655
New +$660K 0.15% 184
2022
Q3 		– Sell
-6,219
Closed -$355K – 663
2022
Q2 		$355K Sell
6,219
-4,504
-42% -$255K 0.14% 226
2022
Q1 		$656K Buy
+10,723
New +$557K 0.09% 274
2020
Q2 		– Sell
-30,100
Closed -$463K – 595
2020
Q1 		$463K Buy
+30,100
New +$654K 0.12% 230

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Seven Eight Capital's ITCI Position: Q4 2024 in Review

Seven Eight Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2024, closing a stake of 10,742 shares — an estimated $786K sold.

Seven Eight Capital first reported a position in ITCI in Q1 2020 and held it in 7 quarters. The position peaked at $1.5M in Q2 2024. 387 funds tracked by Wall St. Rank hold ITCI as of Q4 2024.

  • Seven Eight Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 10,742 Intra-Cellular Therapies Inc. shares in Q4 2024, an estimated $786K.
  • Seven Eight Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2020 and held it in 7 quarters.
  • Seven Eight Capital's Intra-Cellular Therapies Inc. position peaked at $1.5M in Q2 2024.
  • 387 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.